These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25898560)

  • 1. [Effect and safety of testosterone undecanoate in the treatment of late-onset hypogonadism: a meta-analysis].
    Zheng Y; Shen XB; Zhou YZ; Ma J; Shang XJ; Shi YJ
    Zhonghua Nan Ke Xue; 2015 Mar; 21(3):263-71. PubMed ID: 25898560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: a meta-analysis of randomized controlled trials.
    Nian Y; Ding M; Hu S; He H; Cheng S; Yi L; Li Y; Wang Y
    Andrologia; 2017 May; 49(4):. PubMed ID: 27389320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
    Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
    Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable testosterone undecanoate for the treatment of hypogonadism.
    Corona G; Maseroli E; Maggi M
    Expert Opin Pharmacother; 2014 Sep; 15(13):1903-26. PubMed ID: 25080279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study.
    Tan WS; Low WY; Ng CJ; Tan WK; Tong SF; Ho C; Khoo EM; Lee G; Lee BC; Lee V; Tan HM
    BJU Int; 2013 Jun; 111(7):1130-40. PubMed ID: 23651425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The method of tonifying kidneys and activating blood circulation increases testosterone secretion index in late-onset hypogonadism males with kidney deficiency].
    Zhou SH; Weng ZW; Li TL
    Zhonghua Nan Ke Xue; 2013 Jul; 19(7):647-51. PubMed ID: 23926685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections.
    Handelsman DJ; Desai R; Conway AJ; Shankara-Narayana N; Stuckey BGA; Inder WJ; Grossmann M; Yeap BB; Jesudason D; Ly LP; Bracken K; Wittert GA
    Eur J Endocrinol; 2022 Jan; 186(3):307-318. PubMed ID: 35000898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
    Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
    Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism].
    Amano T
    Clin Calcium; 2013 Aug; 23(8):1179-84. PubMed ID: 23892219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.
    Cui Y; Zong H; Yang C; Yan H; Zhang Y
    Int Urol Nephrol; 2013 Aug; 45(4):979-87. PubMed ID: 23728850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral Testosterone Undecanoate Capsules combined with Qilin Pills for late-onset hypogonadism in males].
    Mao JB; Chen XG; Gui DW; Peng W; Zheng J
    Zhonghua Nan Ke Xue; 2017 May; 23(5):455-458. PubMed ID: 29717839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.